Anaemia of chronic kidney disease (renal anaemia)
renal anaemia · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Normochromic normocytic anaemia from reduced erythropoietin production and functional iron deficiency in CKD. Management requires iron repletion before and alongside erythropoiesis-stimulating agents (ESAs) or HIF-PH inhibitors, targeting haemoglobin 100-120 g/L (not normal).
Red flags
- Hb falling rapidly or symptomatic anaemia with chest pain/dyspnoea
- Evidence of active GI bleeding
- ESA hyporesponsiveness despite iron repletion
- Pure red cell aplasia (anti-EPO antibodies) — sudden transfusion dependence
- Thrombotic event on ESA with over-target Hb
Assessment
Differential diagnosis
- Erythropoietin deficiency of CKD
- Absolute/functional iron deficiency
- Blood loss (GI, dialysis circuit)
- B12/folate deficiency
- Haemolysis or marrow suppression
- Underlying haematological malignancy / myeloma
Investigations
- FBC with indices and reticulocytes
- Ferritin and transferrin saturation (TSAT)
- B12, folate
- CRP (inflammation causes functional iron deficiency)
- Renal function and CKD stage
- Haematinics plus blood film / myeloma screen if atypical (e.g. very low or disproportionate anaemia)
Management
- Confirm anaemia attributable to CKD and exclude other causes (iron, B12, folate, blood loss, haemolysis, malignancy)
- Check iron status: aim TSAT >20% and ferritin >100 micrograms/L (non-dialysis) / >200 micrograms/L (haemodialysis)
- Replete iron first: oral iron trial in non-dialysis CKD, IV iron if oral ineffective/not tolerated or in haemodialysis
- Only start an ESA once iron replete and reversible causes addressed
- Set individualised Hb target 100-120 g/L; do not aim for normal Hb (higher targets increase stroke/thrombosis)
- Start ESA (epoetin or darbepoetin) at low dose and titrate by Hb response (rate of rise <20 g/L per 4 weeks)
- Consider an oral HIF-prolyl hydroxylase inhibitor (e.g. roxadustat/daprodustat) as an alternative where available
- Monitor Hb every 2-4 weeks during titration, then monthly when stable
- Control blood pressure before/while on ESA; hold or reduce ESA if BP rises or Hb >120 g/L
- Investigate ESA hyporesponsiveness (iron, inflammation, blood loss, hyperparathyroidism, malignancy)
- Minimise blood loss and transfusion to preserve transplant candidacy
- Reassess iron indices every 1-3 months on treatment
Drugs & doses
Ferrous sulfate 200 mg PO once daily or alternate days (oral trial)
Ferric carboxymaltose IV 500-1000 mg per dose (max 20 mg/kg) as per local protocol
Iron sucrose IV 200 mg per session (common in haemodialysis)
Darbepoetin alfa 0.45 micrograms/kg SC once weekly or 0.75 micrograms/kg every 2 weeks, titrated
Epoetin alfa/beta 50 units/kg SC three times weekly, titrated to Hb
Roxadustat 70-100 mg PO three times weekly (where licensed), titrated
Disposition
Outpatient CKD/renal anaemia clinic. Admit for symptomatic severe anaemia or active bleeding. Haematology referral for suspected pure red cell aplasia or unexplained hyporesponsiveness.
Complications & pitfalls
- Hypertension and stroke/thrombosis from over-correction
- ESA resistance
- Iron overload from excessive IV iron
- Anaphylactoid reactions to IV iron
- Pure red cell aplasia (rare)
- Transfusion sensitisation reducing transplant options
Exam pearls
- Replete iron before escalating ESA dose
- Target Hb 100-120 g/L, never normal — higher targets cause harm
- Functional iron deficiency: low TSAT with normal/high ferritin from inflammation
- Investigate blood loss if ESA requirements rise
- Avoid transfusion where possible in transplant candidates
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.